Evidence map›Paper›PMID 31360836›Full record

ArticleJNCI cancer spectrum2018

Factors Associated With Small Aggressive Non-Small Cell Lung Cancers in the National Lung Screening Trial: A Validation Study.

Matthew T Warkentin, Martin C Tammemägi, Matthew T Freedman, Lawrence R Ragard, William G Hocking, Paul A Kvale, Darren R Brenner, Ping Hu, Thomas L Riley, John Commins and 2 more

Open access · goldAbstract read
In one paragraph

Article in JNCI cancer spectrum, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 2 countries.

Matthew T WarkentinDepartment of Health Sciences, Brock University, St. Catharine's, Ontario, Canada.
Martin C TammemägiDepartment of Health Sciences, Brock University, St. Catharine's, Ontario, Canada.
Matthew T FreedmanCancer Prevention and Control, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC.
Lawrence R RagardWestat, Rockville, MD.
William G HockingDepartment of Clinical Oncology, Marshfield Clinic Health System, Marshfield, WI.
Paul A KvaleDivision of Pulmonary and Critical Care Medicine, Henry Ford Health System, Detroit, MI.
Darren R BrennerDepartment of Cancer Epidemiology and Prevention Research, CancerControl Alberta, Alberta Health Services, Calgary, Alberta, Canada.
Ping HuBiometry Research Group, National Cancer Institute, Bethesda, MD.
Thomas L RileyInformation Management Services, Inc., Rockville, MD.
John ComminsInformation Management Services, Inc., Rockville, MD.
Timothy R ChurchDivision of Environmental Health Sciences, School of Public Health, University of Minnesota, Minneapolis, MN.
Christine D BergDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Information Management Services · USNational Cancer Institute · USAlberta Health Services · CABrock University · CAGeorgetown Lombardi Comprehensive Cancer CenterHenry Ford Health System · USMarshfield Clinic · USUniversity of Calgary · CAUniversity of Minnesota · USWestat (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA small proportion of non-small cell lung cancers (NSCLCs) have been observed to spread to distant lymph nodes (N3) or metastasize (M1) or both, while the primary tumor is small (≤3 cm, T1). These small aggressive NSCLCs (SA-NSLSC) are important as they are clinically significant, may identify unique biologic pathways, and warrant aggressive follow-up and treatment. This study identifies factors associated with SA-NSCLC and attempts to validate a previous finding that women with a family history of lung cancer are at particularly elevated risk of SA-NSCLC.

methodsThis study used a case-case design within the National Cancer Institute's National Lung Screening Trial (NLST) cohort. Case patients and "control" patients were selected based on TNM staging parameters. Case patients (n = 64) had T1 NSCLCs that were N3 or M1 or both, while "control" patients (n = 206) had T2 or T3, N0 to N2, and M0 NSCLCs. Univariate and multivariable logistic regression were used to identify factors associated with SA-NSCLC.

resultsIn bootstrap bias-corrected multivariable logistic regression models, small aggressive adenocarcinomas were associated with a positive history of emphysema (odds ratio [OR] = 5.15, 95% confidence interval [CI] = 1.63 to 23.00) and the interaction of female sex and a positive family history of lung cancer (OR = 6.55, 95% CI = 1.06 to 50.80).

conclusionsEmphysema may play a role in early lung cancer progression. Females with a family history of lung cancer are at increased risk of having small aggressive lung adenocarcinomas. These results validate previous findings and encourage research on the role of female hormones interacting with family history and genetic factors in lung carcinogenesis and progression.

Identifiers

PMID31360836
PMCPMC6649725
OpenAlexW2790034830

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.